Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan;15(1):97-103.
doi: 10.1038/nm.1898. Epub 2009 Jan 4.

Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice

Rory R Koenen  1 , Philipp von Hundelshausen, Irina V Nesmelova, Alma Zernecke, Elisa A Liehn, Alisina Sarabi, Birgit K Kramp, Anna M Piccinini, Søren R Paludan, M Anna Kowalska, Andreas J Kungl, Tilman M Hackeng, Kevin H Mayo, Christian Weber
Affiliations

Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice

Rory R Koenen et al. Nat Med. 2009 Jan.

Abstract

Atherosclerosis is characterized by chronic inflammation of the arterial wall due to chemokine-driven mononuclear cell recruitment. Activated platelets can synergize with chemokines to exacerbate atherogenesis; for example, by deposition of the chemokines platelet factor-4 (PF4, also known as CXCL4) and RANTES (CCL5), triggering monocyte arrest on inflamed endothelium. Homo-oligomerization is required for the recruitment functions of CCL5, and chemokine heteromerization has more recently emerged as an additional regulatory mechanism, as evidenced by a mutual modulation of CXCL8 and CXCL4 activities and by enhanced monocyte arrest resulting from CCL5-CXCL4 interactions. The CCL5 antagonist Met-RANTES reduces diet-induced atherosclerosis; however, CCL5 antagonism may not be therapeutically feasible, as suggested by studies using Ccl5-deficient mice which imply that direct CCL5 blockade would severely compromise systemic immune responses, delay macrophage-mediated viral clearance and impair normal T cell functions. Here we determined structural features of CCL5-CXCL4 heteromers and designed stable peptide inhibitors that specifically disrupt proinflammatory CCL5-CXCL4 interactions, thereby attenuating monocyte recruitment and reducing atherosclerosis without the aforementioned side effects. These results establish the in vivo relevance of chemokine heteromers and show the potential of targeting heteromer formation to achieve therapeutic effects.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clin Immunol. 2002 Mar;102(3):302-9 - PubMed
    1. Biochemistry. 1989 Nov 28;28(24):9469-78 - PubMed
    1. J Biomol NMR. 1994 Sep;4(5):603-14 - PubMed
    1. Nat Rev Immunol. 2008 Oct;8(10):802-15 - PubMed
    1. Biochemistry. 1994 Nov 15;33(45):13436-44 - PubMed

Publication types

MeSH terms

LinkOut - more resources